Fosmidomycin (FR 31564)

Class: DXP reductoisomerase inhibitor (phosphonic acid derivative)

Spectrum of activity:	Gram-positive
Details of activity:	Targets the cell wall; effective against Pseudomonas aeruginosa and E. coli.
Institute where first reported:	Vicuron Pharmaceuticals (Pfizer, USA)
Highest developmental phase:	Phase 2
Development status:	Inactive
Reason Dropped:	Development of resistance due to access into cells through glycerophosphate transporter

Chemical structure(s):
Canonical SMILES:	C(CN(C=O)O)CP(=O)(O)O
Isomeric SMILES:	C(CN(C=O)O)CP(=O)(O)O
InChI:	InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
InChI Key:	GJXWDTUCERCKIX-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/572

External links:
Guide to Pharmacology:	fosmidomycin